Twist Bioscience Co. (NASDAQ:TWST) Shares Sold by Quest Partners LLC

Quest Partners LLC lessened its position in Twist Bioscience Co. (NASDAQ:TWST) by 51.5% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 3,677 shares of the company’s stock after selling 3,901 shares during the period. Quest Partners LLC’s holdings in Twist Bioscience were worth $181,000 as of its most recent SEC filing.

Other institutional investors and hedge funds have also modified their holdings of the company. EdgeRock Capital LLC acquired a new position in Twist Bioscience in the 2nd quarter valued at $43,000. Blue Trust Inc. lifted its position in Twist Bioscience by 2,912.8% during the second quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock worth $58,000 after buying an additional 1,136 shares during the period. Nisa Investment Advisors LLC boosted its stake in Twist Bioscience by 31.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock worth $113,000 after buying an additional 546 shares during the last quarter. CWM LLC grew its holdings in Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after buying an additional 524 shares during the period. Finally, Headlands Technologies LLC acquired a new position in shares of Twist Bioscience during the 1st quarter valued at about $124,000.

Insider Buying and Selling at Twist Bioscience

In other Twist Bioscience news, insider Dennis Cho sold 709 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $28,310.37. Following the transaction, the insider now directly owns 78,996 shares of the company’s stock, valued at approximately $3,154,310.28. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. In related news, SVP Paula Green sold 1,137 shares of Twist Bioscience stock in a transaction dated Monday, August 5th. The stock was sold at an average price of $39.93, for a total value of $45,400.41. Following the completion of the transaction, the senior vice president now directly owns 88,837 shares in the company, valued at $3,547,261.41. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Dennis Cho sold 709 shares of the company’s stock in a transaction that occurred on Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $28,310.37. Following the sale, the insider now owns 78,996 shares in the company, valued at approximately $3,154,310.28. The disclosure for this sale can be found here. Insiders sold a total of 17,388 shares of company stock worth $776,599 in the last 90 days. 3.92% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts recently issued reports on the stock. Guggenheim initiated coverage on shares of Twist Bioscience in a report on Tuesday, June 4th. They issued a “buy” rating and a $53.00 target price for the company. JPMorgan Chase & Co. increased their target price on Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a research report on Monday, August 5th. The Goldman Sachs Group boosted their price target on Twist Bioscience from $45.00 to $55.00 and gave the company a “buy” rating in a research report on Tuesday, July 9th. Barclays reduced their price objective on Twist Bioscience from $60.00 to $55.00 and set an “overweight” rating on the stock in a research note on Monday, August 5th. Finally, TD Cowen raised their price target on shares of Twist Bioscience from $55.00 to $65.00 and gave the company a “buy” rating in a report on Thursday, June 13th. One equities research analyst has rated the stock with a sell rating and eight have given a buy rating to the stock. According to MarketBeat, Twist Bioscience currently has an average rating of “Moderate Buy” and a consensus price target of $48.22.

Twist Bioscience Trading Up 5.3 %

NASDAQ TWST opened at $46.95 on Monday. The company’s fifty day simple moving average is $47.68 and its 200-day simple moving average is $42.77. The stock has a market cap of $2.75 billion, a P/E ratio of -13.97 and a beta of 1.76. Twist Bioscience Co. has a 52 week low of $14.42 and a 52 week high of $60.90.

Twist Bioscience (NASDAQ:TWST) last posted its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.71). The firm had revenue of $81.50 million during the quarter, compared to analysts’ expectations of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business’s quarterly revenue was up 27.7% on a year-over-year basis. During the same period in the previous year, the company earned ($1.01) earnings per share. On average, research analysts expect that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.